Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
Therapeutic Advances in Medical Oncology · 2025-01 · 17
DOI: 10.1177/17588359241295544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 07.01.2025. Verfasst von Youwen Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Research Project of Xiangya Hospital, Changsha Natural Science Foundation of Hunan Provincial of China.
Abstract (Originalsprache)
Background
Both the antibody–drug conjugate (ADC) enfortumab vedotin (EV) and programmed death-1 inhibitor pembrolizumab have been shown to provide survival benefits in patients previously treated with locally advanced or metastatic urothelial carcinoma (la/mUC). Cost-effectiveness is necessary to consider whether the increased efficacy of the two therapies will lead to higher prices for first-line treatment of previously untreated la/mUC.
Objectives
To guide the choice of EV plus pembrolizumab or chemotherapy for patients with previously untreated la/mUC.
Design
The cost-effective analysis.
Methods
A Markov model was developed to simulate the lifetime of patients with previously untreated la/mUC to assess the overall cost and efficacy of EV plus pembrolizumab and chemotherapy based on the EV-302/KEYNOTE-A39 trial. Primary outcomes included total cost, life-years (LYs), quality-adjusted LYs (QALYs), the incremental cost-effectiveness ratio (ICER), and incremental net health benefits at the USA and Chinese willingness-to-pay threshold of $150,000/QALY and $35,173/QALY, respectively. Model stability was examined through sensitivity and subgroup analyses.
Results
EV plus pembrolizumab and chemotherapy treatment regimens were associated with 2.07–2.16 and 1.04–1.06 QALYs with corresponding costs of $288,347–$532,362 and $24,773–$267,568, respectively. ICERs in the United States and China are $267,491/QALY and $254,339/QALY, respectively. The factors that most strongly influenced model outcomes in unidirectional sensitivity analyses were patient weight and the cost of EV. To achieve greater cost-effectiveness, EV costs would need to be reduced by over 75% and 10% in the United States and China, respectively.
Conclusion
While first-line EV plus pembrolizumab has significant health benefits compared to chemotherapy for patients with previously untreated la/mUC, this regimen is not cost-effective at the current price in the United States or China.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
- Department of Oncology, Zhuzhou Second Hospital, Zhuzhou, Hunan 412000, China.
ORCID-Profile: Youwen Zhu, Kun Liu, Hong Zhu
Förderung
- Clinical Research Project of Xiangya Hospital
- Changsha Natural Science Foundation of Hunan Provincial of China
Zitieren
APA
Zhu, Y., Liu, K., Zhu, H., Li, S., & Yuan, D. (2025). Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359241295544
Vancouver
Zhu Y, Liu K, Zhu H, Li S, Yuan D. Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359241295544
BibTeX
@article{Zhu2025,
author = {Zhu, Youwen and Liu, Kun and Zhu, Hong and Li, Shan and Yuan, Dan},
title = {Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis},
journal = {Therapeutic Advances in Medical Oncology},
year = {2025},
volume = {17},
doi = {10.1177/17588359241295544}
}
EUVIMED